Work

Phase III Efficacy of Belumosudil in Chronic Graft-versus-Host Disease: A Structured Congress Abstract

A structured IMRAD-format abstract prepared for EBMT 2024, summarising the pivotal phase III ROCKstar trial results for belumosudil in steroid-refractory chronic GvHD. Written to meet the 350-word limit with full statistical disclosure.

Mechanisms of Primary Resistance to Anti-PD-1 Therapy in Advanced Melanoma: Interim Analysis

A journal submission abstract summarising interim biomarker data from an investigator-initiated study exploring genomic and tumour microenvironment correlates of anti-PD-1 resistance in advanced melanoma.

ASCO 2024 Poster: Tislelizumab Plus Chemotherapy vs Chemotherapy Alone in HER2-Negative Gastric Cancer

A conference poster presented at ASCO 2024 summarising the RATIONALE-305 phase III data in first-line HER2-negative gastric or gastro-oesophageal junction adenocarcinoma. Designed for a 90-second walk-by read time with clear hierarchy and selective data visualisation.

ASH 2023 Poster: Real-World Outcomes with Venetoclax-Based Regimens in Elderly AML Patients Unfit for Intensive Chemotherapy

A retrospective real-world evidence poster presented at ASH 2023, examining clinical outcomes and prognostic factors in AML patients ≥75 years treated with venetoclax plus azacitidine in routine clinical practice across five UK cancer centres.

KOL Advisory Board Slide Deck: CAR-T Sequencing Strategies in R/R DLBCL — ASH 2024 Data Readout

A 28-slide advisory board deck prepared for a European KOL meeting on optimal CAR-T sequencing in relapsed/refractory DLBCL, incorporating updated TRANSFORM and ZUMA-7 data from ASH 2024. Structured to drive 90 minutes of expert discussion.

Disease State Education Slide Deck: Mechanism of Action of Checkpoint Inhibition in NSCLC

A 20-slide HCP education deck explaining PD-1/PD-L1 biology, the rationale for checkpoint inhibition in NSCLC, and a framework for patient selection — designed for oncology nurses and junior physicians at a regional tumour board.

Plain Language Summary: A Study of Venetoclax Plus Azacitidine in Older Adults with Acute Myeloid Leukaemia (AML)

A patient-facing plain language summary of the VIALE-A phase III trial, written to EUPATI standards for adults with AML who are not able to have intensive chemotherapy. Approved for publication on the trial sponsor's patient portal.

Plain Language Summary: A Clinical Trial of a Gene Therapy for Sickle Cell Disease

A plain language summary of a phase I/II gene therapy trial for sickle cell disease, written for patients and carers considering enrolment or seeking to understand results from a completed study.

CD8+ T-cell exhaustion is reversible by combined PD-1 and TIM-3 blockade in a murine model of chronic infection

Nature Communications · 2023

Negi V, Hartmann M, Rousseau C, Singh A, Bhatt DL

Lipid nanoparticle-mediated delivery of CRISPR–Cas9 components achieves efficient in vivo gene editing in primary hepatocytes

Journal of Clinical Investigation · 2022

Negi V, Patel R, Chen W, Obasi M, Steinberg S

Tumour-intrinsic IFN-γ signalling loss confers primary resistance to anti-PD-L1 therapy in NSCLC

Cancer Cell · 2021

Negi V, Walters K, Domingo-Fernandez D, Agarwal P

CAR-T cell therapy in diffuse large B-cell lymphoma: mechanisms of durable response and immune editing

Blood · 2020

Negi V, Ashton-Prolla P, Ferreira LM, Kang I

Single-cell transcriptomics reveals heterogeneity in myeloid-derived suppressor cell populations within the glioblastoma microenvironment

PLOS Biology · 2019

Negi V, Tanaka Y, Muthukrishnan N, Okonkwo D